Joel Greenblatt Myriad Genetics Inc Transaction History

Gotham Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$12.16 - $19.77 $162,056 - $263,474	-13,327 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$11.25 - $14.75 $149,928 - $196,573	13,327 New	13,327 $174,000
Q2 2019 Aug 14, 2019	SELL	$22.67 - $35.0 $454,646 - $701,925	-20,055 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$26.93 - $34.7 $138,554 - $178,531	5,145 Added 34.51%	20,055 $666,000
Q4 2018 Feb 14, 2019	SELL	$27.23 - $45.56 $836,478 - $1.4 Million	-30,719 Reduced 67.32%	14,910 $433,000
Q3 2018 Nov 14, 2018	BUY	$37.57 - $50.34 $821,956 - $1.1 Million	21,878 Added 92.11%	45,629 $2.1 Million
Q2 2018 Aug 14, 2018	SELL	$27.75 - $40.17 $255,855 - $370,367	-9,220 Reduced 27.96%	23,751 $888,000
Q1 2018 May 15, 2018	SELL	$28.83 - $41.01 $3.22 Million - $4.58 Million	-111,800 Reduced 77.23%	32,971 $974,000
Q4 2017 Feb 14, 2018	SELL	$28.45 - $37.14 $2.11 Million - $2.76 Million	-74,321 Reduced 33.92%	144,771 $4.97 Million
Q3 2017 Nov 14, 2017	BUY	$24.01 - $36.2 $5.26 Million - $7.93 Million	219,092	219,092 $7.93 Million

227

92M

297K

20.7K

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.14B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.